United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $586.66, for a total transaction of $5,573,270.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,767,356.58. This represents a 19.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

United Therapeutics Price Performance

NASDAQ UTHR opened at $573.44 on Tuesday. The company’s 50 day simple moving average is $528.74 and its two-hundred day simple moving average is $491.26. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89. The stock has a market capitalization of $25.13 billion, a PE ratio of 20.55, a P/E/G ratio of 1.68 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned $6.19 EPS. On average, research analysts anticipate that United Therapeutics Corporation will post 27.93 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on UTHR. Morgan Stanley upped their target price on United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. TD Cowen boosted their price objective on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. HC Wainwright raised their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Finally, Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $601.50.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its position in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the last quarter. Jump Financial LLC purchased a new stake in United Therapeutics in the second quarter worth approximately $277,000. Cerity Partners LLC grew its position in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after acquiring an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia grew its position in United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Company-reported clinical data to be presented at ISHLT (ARTISAN and PHINDER interim analyses) suggest earlier detection/management benefits in pulmonary hypertension, right-ventricular improvement with high‑dose treprostinil, and broader pipeline visibility including lung donor expansion and xenotransplantation — these findings can support longer-term revenue and pipeline value. United Therapeutics Presents New Data at ISHLT 2026
• Positive Sentiment: Analyst consensus remains constructive — UTHR carries an average recommendation of “Moderate Buy,” which can underpin investor confidence and valuation support amid near-term volatility. United Therapeutics Given Average Recommendation of Moderate Buy
• Neutral Sentiment: A comparative valuation piece (CPRX vs UTHR) discusses which is a better value — useful context for value-oriented investors but not company-specific news likely to move the stock materially on its own. CPRX or UTHR: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Unusually large options trading was reported, indicating elevated short-term interest or hedging activity — this can amplify intraday moves but is ambiguous on direction. United Therapeutics Target of Unusually Large Options Trading
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.57M) on April 17 and reduced her stake by ~19% in that filing — large insider sales often trigger investor concern about near-term outlook or personal liquidity needs. SEC Filing – CEO Insider Sale
• Negative Sentiment: Additional recent insider sales reported: CFO sale totaling about $5.77M and a director sale of ~$578.9k — multiple senior-level sales in close succession increase perceived selling pressure. CFO Insider Sale Director Insider Sale
• Negative Sentiment: Earlier small CEO sale (~$40k) was also disclosed — while smaller, it adds to the sequence of insider disposals that investors are noting. CEO Insider Sale (smaller)

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.